<p>大西洋联合银行股份公司在最近向证券交易委员会提交的文件中表示，在第二季度其在诺华制药（NYSE:NVS - 免费报告）的持股增长了 62.4%。该机构投资者在此期间购买了额外的 10,969 股后，持有该公司 28,557 股股票。截至其最近向证券交易委员会提交的文件，大西洋联合银行股份公司在诺华的持股价值为 3,456,000 美元。</p>
<ul>
<li>诺华的月球计划癌症疗法可能成为未来的增长驱动力</li>
</ul>
<p>其他几家对冲基金最近也对其在 NVS 的持仓进行了调整。Dimensional Fund Advisors LP 在第一季度将其在诺华的持仓增加了 5.2%。Dimensional Fund Advisors LP 目前持有 8,606,724 股该公司的股票，价值为 959,535,000 美元，此前在上个季度又收购了 422,869 股。高盛集团在第一季度将其在诺华的股份增加了 60.3%。高盛集团目前持有 3,660,485 股该公司的股票，价值为 408,071,000 美元，此前在上个季度又购买了 1,377,252 股。北方信托公司在第一季度将其在诺华的持股增加了 2.2%。北方信托公司目前持有 2,180,281 股该公司的股票，价值为 243,058,000 美元，此前在此期间又购买了 47,690 股。Envestnet 资产管理公司在第二季度将其在诺华的持仓增加了 8.0%。Envestnet 资产管理公司目前持有 1,736,891 股该公司的股票，价值为 210,181,000 美元，此前在上个季度又购买了 128,302 股。最后，New Vernon Capital Holdings II LLC 在第一季度将其在诺华的持仓增加了 12,664.1%。New Vernon Capital Holdings II LLC 目前持有 1,383,244 股该公司的股票，价值为 154,204,000 美元，此前在上个季度又购买了 1,372,407 股。目前，13.12% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>诺华股价上涨 1.0%</h2>
<p>周五，NYSE NVS 的股票开盘价为 126.71 美元。诺华制药的 12 个月低点为 96.06 美元，12 个月高点为 133.55 美元。该公司的市值为 2676.5 亿美元，市盈率为 17.31，市盈增长比率为 1.93，贝塔值为 0.60。该公司的 50 日简单移动平均为 127.30 美元，200 日简单移动平均为 120.55 美元。该公司的速动比率为 0.62，流动比率为 0.88，债务与股本比率为 0.50。</p>
<ul>
<li>三只大型制药股在美国投资超过 1000 亿美元。</li>
</ul>
<p>诺华（NYSE:NVS - 获取免费报告）最近于 10 月 28 日（星期二）公布了季度财报。该公司报告季度每股收益为 2.25 美元，低于市场共识预期的 2.26 美元（差额为 0.01 美元）。诺华的净利润率为 26.49%，股本回报率为 41.21%。该公司季度收入为 139.1 亿美元，而分析师预期为 137 亿美元。在去年同期，该公司的每股收益为 2.06 美元。该公司的季度收入同比增长了 8.5%。分析师预计诺华制药在当前财年将发布每股收益 8.45 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位股票研究分析师最近对该股票发表了看法。高盛集团在 9 月 12 日的研究报告中重申了对诺华的 “卖出” 评级，并将目标价下调至 118.00 美元（之前为 119.00 美元）。HC Wainwright 在 10 月 27 日的研究报告中将诺华的股票评级下调至 “中性”。Cfra 在 10 月 29 日的研究报告中对诺华的股票设定了 126.00 美元的目标价，并给予该股票 “持有” 评级。德意志银行在 8 月 21 日的研究报告中重申了对诺华的 “买入” 评级。最后，摩根士丹利在 10 月 31 日的研究报告中将诺华的评级从 “持平” 上调至 “增持”。一位研究分析师对该股票给予了强烈买入评级，三位给予买入评级，六位给予持有评级，三位给予卖出评级。根据 MarketBeat 的数据，诺华的共识评级为 “持有”，平均目标价为 122.33 美元。</p>
<ul>
<li>三只可能在市场波动后飙升的动量股</li>
</ul>
<p><strong>查看我们关于诺华的最新报告</strong></p>
<h2>关于诺华</h2>
<p>（免费报告）</p>
<p>诺华制药股份有限公司在瑞士及国际上从事医疗产品的研究、开发、生产和营销。该公司为患者和医生提供处方药。它专注于心血管、肾脏和代谢、免疫学、神经科学和肿瘤学等治疗领域，以及眼科和血液学。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过诺华</li>
<li>投资旅游股票的好处</li>
<li>CAVA 股票在财报失利后寻找方向</li>
<li>投资汽车股票</li>
<li>三只准备爆发的小型 AI 股票（均在 20 美元以下）</li>
<li>加拿大便士股票：它们能让你致富吗？</li>
<li>在下跌 16% 后，分析师关注 Meta Platforms 的大幅复苏</li>
</ul>
<p><strong>想看看其他对冲基金持有的 NVS 吗？</strong> 访问 HoldingsChannel.com 获取诺华制药（NYSE:NVS - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw"/></p>
<p><em>此即时新闻提醒是由叙述科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在诺华吗？</h2>
<p>在考虑诺华之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而诺华并不在名单上。</p>
<p>虽然诺华目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>大西洋联盟银行股份公司在第二季度将其在诺华制药公司的持股增加了 62.4%，目前持有 28,557 股，价值 346 万美元。其他机构投资者也增加了他们的持股，维度基金顾问增加了 5.2%，高盛则增加了 60.3%。诺华的股票开盘价为 126.71 美元，市值为 2676.5 亿美元。该公司报告第三季度每股收益为 2.25 美元，略低于预期，但收入同比增长了 8.5%。分析师对诺华的评级意见不一，普遍评级为 “持有”，平均目标价为 122.33 美元</p>

<p>Atlantic Union Bankshares Corp grew its holdings in Novartis AG (NYSE:NVS - Free Report) by 62.4% in the second quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The institutional investor owned 28,557 shares of the company's stock after buying an additional 10,969 shares during the period. Atlantic Union Bankshares Corp's holdings in Novartis were worth $3,456,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>大西洋联合银行股份公司在最近向证券交易委员会提交的文件中表示，在第二季度其在诺华制药（NYSE:NVS - 免费报告）的持股增长了 62.4%。该机构投资者在此期间购买了额外的 10,969 股后，持有该公司 28,557 股股票。截至其最近向证券交易委员会提交的文件，大西洋联合银行股份公司在诺华的持股价值为 3,456,000 美元。</p>
</div><ul>
<li>Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver</li>
</ul>
<div class="lb-trans"><ul>
<li>诺华的月球计划癌症疗法可能成为未来的增长驱动力</li>
</ul>
</div><p>Several other hedge funds have also recently made changes to their positions in NVS. Dimensional Fund Advisors LP grew its position in Novartis by 5.2% in the first quarter. Dimensional Fund Advisors LP now owns 8,606,724 shares of the company's stock worth $959,535,000 after acquiring an additional 422,869 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Novartis by 60.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 3,660,485 shares of the company's stock valued at $408,071,000 after purchasing an additional 1,377,252 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of Novartis by 2.2% in the 1st quarter. Northern Trust Corp now owns 2,180,281 shares of the company's stock worth $243,058,000 after purchasing an additional 47,690 shares during the period. Envestnet Asset Management Inc. increased its position in shares of Novartis by 8.0% during the 2nd quarter. Envestnet Asset Management Inc. now owns 1,736,891 shares of the company's stock valued at $210,181,000 after purchasing an additional 128,302 shares during the last quarter. Finally, New Vernon Capital Holdings II LLC lifted its position in Novartis by 12,664.1% in the first quarter. New Vernon Capital Holdings II LLC now owns 1,383,244 shares of the company's stock worth $154,204,000 after buying an additional 1,372,407 shares during the last quarter. 13.12% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他几家对冲基金最近也对其在 NVS 的持仓进行了调整。Dimensional Fund Advisors LP 在第一季度将其在诺华的持仓增加了 5.2%。Dimensional Fund Advisors LP 目前持有 8,606,724 股该公司的股票，价值为 959,535,000 美元，此前在上个季度又收购了 422,869 股。高盛集团在第一季度将其在诺华的股份增加了 60.3%。高盛集团目前持有 3,660,485 股该公司的股票，价值为 408,071,000 美元，此前在上个季度又购买了 1,377,252 股。北方信托公司在第一季度将其在诺华的持股增加了 2.2%。北方信托公司目前持有 2,180,281 股该公司的股票，价值为 243,058,000 美元，此前在此期间又购买了 47,690 股。Envestnet 资产管理公司在第二季度将其在诺华的持仓增加了 8.0%。Envestnet 资产管理公司目前持有 1,736,891 股该公司的股票，价值为 210,181,000 美元，此前在上个季度又购买了 128,302 股。最后，New Vernon Capital Holdings II LLC 在第一季度将其在诺华的持仓增加了 12,664.1%。New Vernon Capital Holdings II LLC 目前持有 1,383,244 股该公司的股票，价值为 154,204,000 美元，此前在上个季度又购买了 1,372,407 股。目前，13.12% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Novartis Trading Up 1.0%</h2>
<div class="lb-trans"><h2>诺华股价上涨 1.0%</h2>
</div><p>Shares of NYSE NVS opened at $126.71 on Friday. Novartis AG has a twelve month low of $96.06 and a twelve month high of $133.55. The firm has a market cap of $267.65 billion, a PE ratio of 17.31, a price-to-earnings-growth ratio of 1.93 and a beta of 0.60. The business has a fifty day simple moving average of $127.30 and a two-hundred day simple moving average of $120.55. The company has a quick ratio of 0.62, a current ratio of 0.88 and a debt-to-equity ratio of 0.50.</p>
<div class="lb-trans"><p>周五，NYSE NVS 的股票开盘价为 126.71 美元。诺华制药的 12 个月低点为 96.06 美元，12 个月高点为 133.55 美元。该公司的市值为 2676.5 亿美元，市盈率为 17.31，市盈增长比率为 1.93，贝塔值为 0.60。该公司的 50 日简单移动平均为 127.30 美元，200 日简单移动平均为 120.55 美元。该公司的速动比率为 0.62，流动比率为 0.88，债务与股本比率为 0.50。</p>
</div><ul>
<li>3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.</li>
</ul>
<div class="lb-trans"><ul>
<li>三只大型制药股在美国投资超过 1000 亿美元。</li>
</ul>
</div><p>Novartis (NYSE:NVS - Get Free Report) last announced its quarterly earnings results on Tuesday, October 28th. The company reported $2.25 EPS for the quarter, missing the consensus estimate of $2.26 by ($0.01). Novartis had a net margin of 26.49% and a return on equity of 41.21%. The firm had revenue of $13.91 billion for the quarter, compared to analysts' expectations of $13.70 billion. During the same quarter in the prior year, the business posted $2.06 EPS. The business's quarterly revenue was up 8.5% on a year-over-year basis. Analysts expect that Novartis AG will post 8.45 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>诺华（NYSE:NVS - 获取免费报告）最近于 10 月 28 日（星期二）公布了季度财报。该公司报告季度每股收益为 2.25 美元，低于市场共识预期的 2.26 美元（差额为 0.01 美元）。诺华的净利润率为 26.49%，股本回报率为 41.21%。该公司季度收入为 139.1 亿美元，而分析师预期为 137 亿美元。在去年同期，该公司的每股收益为 2.06 美元。该公司的季度收入同比增长了 8.5%。分析师预计诺华制药在当前财年将发布每股收益 8.45 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several equities research analysts have recently weighed in on the stock. The Goldman Sachs Group reissued a &#34;sell&#34; rating and issued a $118.00 target price (down previously from $119.00) on shares of Novartis in a research note on Friday, September 12th. HC Wainwright lowered shares of Novartis to a &#34;neutral&#34; rating in a research report on Monday, October 27th. Cfra set a $126.00 price objective on shares of Novartis and gave the stock a &#34;hold&#34; rating in a research note on Wednesday, October 29th. Deutsche Bank Aktiengesellschaft reaffirmed a &#34;buy&#34; rating on shares of Novartis in a research note on Thursday, August 21st. Finally, Morgan Stanley raised Novartis from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating in a research note on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, six have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, Novartis has a consensus rating of &#34;Hold&#34; and an average target price of $122.33.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该股票发表了看法。高盛集团在 9 月 12 日的研究报告中重申了对诺华的 “卖出” 评级，并将目标价下调至 118.00 美元（之前为 119.00 美元）。HC Wainwright 在 10 月 27 日的研究报告中将诺华的股票评级下调至 “中性”。Cfra 在 10 月 29 日的研究报告中对诺华的股票设定了 126.00 美元的目标价，并给予该股票 “持有” 评级。德意志银行在 8 月 21 日的研究报告中重申了对诺华的 “买入” 评级。最后，摩根士丹利在 10 月 31 日的研究报告中将诺华的评级从 “持平” 上调至 “增持”。一位研究分析师对该股票给予了强烈买入评级，三位给予买入评级，六位给予持有评级，三位给予卖出评级。根据 MarketBeat 的数据，诺华的共识评级为 “持有”，平均目标价为 122.33 美元。</p>
</div><ul>
<li>3 Momentum Stocks That Could Soar Post-Market Volatility</li>
</ul>
<div class="lb-trans"><ul>
<li>三只可能在市场波动后飙升的动量股</li>
</ul>
</div><p><strong>View Our Latest Report on Novartis</strong></p>
<div class="lb-trans"><p><strong>查看我们关于诺华的最新报告</strong></p>
</div><h2>About Novartis</h2>
<div class="lb-trans"><h2>关于诺华</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.</p>
<div class="lb-trans"><p>诺华制药股份有限公司在瑞士及国际上从事医疗产品的研究、开发、生产和营销。该公司为患者和医生提供处方药。它专注于心血管、肾脏和代谢、免疫学、神经科学和肿瘤学等治疗领域，以及眼科和血液学。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Novartis</li>
<li>Investing in Travel Stocks Benefits</li>
<li>CAVA Stock Looking for Direction After Earnings Miss</li>
<li>Investing In Automotive Stocks</li>
<li>3 Small AI Stocks Ready to Explode (All Under $20)</li>
<li>Canadian Penny Stocks: Can They Make You Rich?</li>
<li>After 16% Fall, Analysts Eye a Big Recovery in Meta Platforms</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过诺华</li>
<li>投资旅游股票的好处</li>
<li>CAVA 股票在财报失利后寻找方向</li>
<li>投资汽车股票</li>
<li>三只准备爆发的小型 AI 股票（均在 20 美元以下）</li>
<li>加拿大便士股票：它们能让你致富吗？</li>
<li>在下跌 16% 后，分析师关注 Meta Platforms 的大幅复苏</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding NVS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 NVS 吗？</strong> 访问 HoldingsChannel.com 获取诺华制药（NYSE:NVS - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=NVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒是由叙述科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Novartis Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在诺华吗？</h2>
</div><p>Before you consider Novartis, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑诺华之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而诺华并不在名单上。</p>
</div><p>While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然诺华目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Atlantic Union Bankshares Corp 增加了其在诺华公司 $NVS 的股票持有量